<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Some children with <z:hpo ids='HP_0000729'>autism spectrum disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e>; 15% to 30% of patients) show a significant and persistent regression in speech and social function during early childhood </plain></SENT>
<SENT sid="1" pm="."><plain>There are no established treatments for the regressive symptoms </plain></SENT>
<SENT sid="2" pm="."><plain>However, there are some known causes of this type of regression, such as <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e> and <z:e sem="disease" ids="C0282512" disease_type="Mental or Behavioral Dysfunction" abbrv="LKS">Landau-Kleffner syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LKS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LKS</z:e>, steroids have been used as a treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Some evidence suggests an autoimmune contribution to the pathophysiology of <z:hpo ids='HP_0000717'>autism</z:hpo> (Chez MG, Guido-Estrada N: Immune therapy in <z:hpo ids='HP_0000717'>autism</z:hpo>: historical experience and future directions with immunomodulatory therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Neurotherapeutics 2010, 7:293-301, Wasilewska J, Kaczmarski M, Stasiak-Barmuta A, Tobolczyk J, Kowalewska E: Low serum IgA and increased expression of CD23 on B lymphocytes in peripheral blood in children with regressive <z:hpo ids='HP_0000717'>autism</z:hpo> aged 3-6 years old </plain></SENT>
<SENT sid="6" pm="."><plain>Arch Med Sci 2012, 8:324-331, Stefanatos G: Changing perspectives on <z:e sem="disease" ids="C0282512" disease_type="Mental or Behavioral Dysfunction" abbrv="LKS">Landau-Kleffner syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Clin Neuropsychol 2011, 25:963-988), raising the possibility that steroids might be a useful therapy for regression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>A retrospective study published in BMC Neurology by Duffy et al </plain></SENT>
<SENT sid="9" pm="."><plain>(Duffy, et al: <z:chebi fb="0" ids="50858">Corticosteroid</z:chebi> therapy in regressive <z:hpo ids='HP_0000717'>autism</z:hpo>: A retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior </plain></SENT>
<SENT sid="10" pm="."><plain>BMC Neurol 2014, 14:70) reviewed 20 steroid treated R-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ASD</z:e> (STAR) patients and 24 ASD control patients not treated with steroids (NSA) </plain></SENT>
<SENT sid="11" pm="."><plain>Improvements in clinical function and in a neurophysiological biomarker were seen in the steroid-treated children pre- to post-<z:chebi fb="2" ids="8378">prednisolone</z:chebi> treatment </plain></SENT>
<SENT sid="12" pm="."><plain>This research provides a rationale for a randomized trial with steroid therapy to determine the longer term benefits and complications of steroids in this population </plain></SENT>
</text></document>